secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0000950170-22-012381
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target
--------------------------------------------------------------------------------

- Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.
- Fate receives research funding through Sep 2024 and is eligible for an option exercise fee, milestones, and tiered royalties.
- Fate retains global manufacturing rights and the right to co-develop and co-commercialize in the US and Europe.
- First iPSC-derived CAR T-cell product candidate targeting solid tumors is advancing toward clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/0000950170-22-012381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022012381/fate-20220628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer